Laura J. Esserman

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

5.3Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 88 papers — median percentile 72. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence

JAMA(2024)10.1001/jama.2024.0268

N/A

0.940DataRank · unranked

25 citations

Caroline Marra, Atul Janardhan Butte, Laura Esserman, Lee A. Fleisher, Cynthia I. Grossman +64 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

EClinicalMedicine(2023)10.1016/j.eclinm.2023.101889

N/A

0.787DataRank · unranked

35 citations

Neil R. Aggarwal, Timothy E. Albertson, Sara C. Auld, Jeremy R. Beitler, Paul Berger +86 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

The Integration of Clinical Trials With the Practice of Medicine

JAMA(2024)10.1001/jama.2024.4088

N/A

0.609DataRank · unranked

57 citations

Alison J. Huang, Roger J. Lewis, Amy P. Abernethy, Robert M. Califf, Martin Landray +63 more

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06914-2

N/A

0.441DataRank · unranked

7 citations

Rebecca Shatsky, Richard B. Schwab, Anne M. Wallace, Denise M. Wolf, Gillian L. Hirst +7 more

Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment

Radiology Imaging Cancer(2023)10.1148/rycan.220126

N/A

0.373DataRank · unranked

8 citations

Teffany Joy Bareng, Jessica Gibbs, Wen Li, Elissa R. Price, Bonnie N. Joe +93 more

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

JAMIA Open(2021)10.1093/jamiaopen/ooab038

Top 51%

0.346DataRank

Top 51%2 citations

David L. Gibbs, Kawther Abdilleh, Adam L. Asare, Smita Asare, Sara J. Venters +8 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer

Journal of the American Medical Informatics Association(2024)10.1093/jamia/ocae190

N/A

0.165DataRank · unranked

2 citations

Anika Christofferson, Saumya Umashankar, Michelle Melisko, Paolo Castillo, Thelma Brown +15 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

medRxiv(2022)10.1101/2022.08.26.22278957

N/A

0.165DataRank · unranked

2 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control

Contemporary Clinical Trials(2024)10.1016/j.cct.2024.107697

N/A

0.104DataRank · unranked

1 citations

Dinesh Pal Mudaranthakam, Byron J. Gajewski, Kate Young, Onalisa Winblad, Seema A. Khan +14 more

Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response

Radiology(2021)10.1148/radiol.2021203645

N/A

0DataRank · unranked

37 citations

Wen Li, David C. Newitt, Roy Harnish, Fredrik Strand, Alex Nguyen +56 more

Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial

npj Breast Cancer(2021)10.1038/s41523-021-00288-8

N/A

0DataRank · unranked

31 citations

Yash S. Huilgol, Yiwey Shieh, Jeffrey A. Tice, Jeffrey Belkora, Karen Sepucha +8 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

JAMA Network Open(2021)10.1001/jamanetworkopen.2021.14904

N/A

0DataRank · unranked

24 citations

Annelie Johansson, Anna Nordenskjöld, Adina Iftimi, Christina Yau, Gizeh Pérez‐Tenorio +7 more

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study

npj Breast Cancer(2021)10.1038/s41523-021-00366-x

N/A

0DataRank · unranked

24 citations

Amy M. Shui, Michelle Melisko, A. Jo Chien, Emi Yoshida, Elizabeth Lancaster +4 more

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer(2021)10.1038/s41523-021-00233-9

N/A

0DataRank · unranked

23 citations

Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola M. Hylton +7 more

Combinatorial Immunotherapies Overcome MYC-Driven Immune Evasion

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.07.442684

N/A

0DataRank · unranked

4 citations

Filomena Housley, Christina Yau, Daniel Van de Mark, Rachel Nakagawa, Golzar Hemmati +11 more

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

Nature Communications(2022)10.1038/s41467-022-31238-y

N/A

0DataRank · unranked

76 citations

Filomena Housley, Christina Yau, Rachel Nakagawa, Juliane Winkler, Johanna M. Anttila +18 more

Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

Nature Medicine(2022)10.1038/s41591-021-01617-x

N/A

0DataRank · unranked

23 citations

Carolyn S. Calfee, Kathleen D. Liu, Adam L. Asare, Jeremy R. Beitler, Paul Berger +95 more

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Cancers(2022)10.3390/cancers14184436

N/A

0DataRank · unranked

23 citations

Nu N. Le, Natsuko Onishi, David C. Newitt, Lisa J. Wilmes, Jessica Gibbs +15 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

International Journal of Cancer(2022)10.1002/ijc.33969

N/A

0DataRank · unranked

19 citations

Nancy Yu, Adina Iftimi, Nicholas P. Tobin, Laura van 't Veer, Bo Nordenskjöld +8 more

Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ : Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Cancer Research Communications(2022)10.1158/2767-9764.crc-22-0263

N/A

0DataRank · unranked

13 citations

Phoebe Miller, Heather Greenwood, Cristian K. Maldonado Rodas, Rita I. Freimanis, Amrita Basu +10 more

The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

npj Breast Cancer(2022)10.1038/s41523-021-00365-y

N/A

0DataRank · unranked

20 citations

Adam Officer, Hidetoshi Mori, Jonathan Gordon, Mark Evans, J. S. Steward +13 more

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer

Tomography(2022)10.3390/tomography8030099

N/A

0DataRank · unranked

7 citations

Wen Li, Natsuko Onishi, David C. Newitt, Jessica Gibbs, Lisa J. Wilmes +8 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0DataRank · unranked

175 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study

Radiology(2023)10.1148/radiol.222733

N/A

0DataRank · unranked

91 citations

Laurel A. Habel, Ninah Achacoso, Diana S.M. Buist, Jason B. Cord, Laura J. Esserman +15 more

Changes in Surgical Management of the Axilla Over 11 Years – Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial

Annals of Surgical Oncology(2023)10.1245/s10434-023-13759-y

N/A

0DataRank · unranked

42 citations

Hongmei Yu, Catherine Lu Dugan, Mara A. Piltin, Lauren M. Postlewait, Jennifer D. Son +32 more

Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification

Nature Reviews Endocrinology(2023)10.1038/s41574-023-00883-8

N/A

0DataRank · unranked

33 citations

Ursula B Kaiser, P Chanson, Mônica R. Gadelha, John Wass, Lynnette K. Nieman +16 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy

Annals of Surgical Oncology(2023)10.1245/s10434-023-13881-x

N/A

0DataRank · unranked

14 citations

Elle Clelland, Firdows Mujir, Helena Record, Jasmine Wong, Laura J. Esserman +4 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

npj Precision Oncology(2023)10.1038/s41698-023-00382-z

N/A

0DataRank · unranked

11 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes

Cancer Epidemiology Biomarkers & Prevention(2023)10.1158/1055-9965.epi-22-1353

N/A

0DataRank · unranked

7 citations

Anne Patterson, Julissa Molina-Vega, Harriet Rothschild, Elle Clelland, Cheryl A. Ewing +5 more

374P Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.552

N/A

0DataRank · unranked

1 citations

Saumya Umashankar, Muneeb M. Musthafa, Thomas Jones, Kasey Blevins, Timothy D. Brown +15 more

Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.28.534564

N/A

0DataRank · unranked

3 citations

Rory Sheng, Elizabeth Murray, Yusuke Ito, Michael Brück, Cassidy Biellak +10 more

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.611

N/A

0DataRank · unranked

2 citations

Hongmei Yu, Denise M. Wolf, Nisha Acharya, Susie Brain, Carol A. Simmons +8 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1572

N/A

0DataRank · unranked

1 citations

Teresa Helsten, Brian Moore, Linda Neuhauser, Barbara LeStage, Paolo Castillo +12 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Data from Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes

(2023)10.1158/1055-9965.c.6706644

N/A

0DataRank · unranked

0 citations

Anne Patterson, Julissa Molina-Vega, Harriet Rothschild, Elle Clelland, Cheryl A. Ewing +5 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0DataRank · unranked

13 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae268

N/A

0DataRank · unranked

5 citations

Huma Dar, Anna Nordenskjöld, Gizeh Pérez‐Tenorio, Nicholas P. Tobin, Christina Yau +8 more

18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy

Radiology Imaging Cancer(2024)10.1148/rycan.230082

N/A

0DataRank · unranked

3 citations

Natsuko Onishi, Deep Hathi, Courtney Lawhn-Heath, John Kornak, Wen Li +12 more

Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ

npj Breast Cancer(2024)10.1038/s41523-024-00677-9

N/A

0DataRank · unranked

3 citations

Cristian K. Maldonado Rodas, Rita I. Freimanis, Alexa Glencer, Phoebe Miller, Rita A. Mukhtar +10 more

Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.19.585748

N/A

0DataRank · unranked

6 citations

Jung Min Suh, Brian J Woo, Albertas Navickas, Kristle Garcia, Keyi Yin +11 more

Tumor microenvironmental determinants of high-risk DCIS progression

Research Square(2024)10.21203/rs.3.rs-4126092/v1

N/A

0DataRank · unranked

2 citations

Alexa Glencer, Kirithiga Ramalingam, Nicole Schindler, Hidetoshi Mori, Parchi Ghule +13 more

Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers

Research Square(2024)10.21203/rs.3.rs-3403438/v1

N/A

0DataRank · unranked

1 citations

Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim +7 more

Implantation of engineered adipocytes suppresses tumor progression in cancer models

Nature Biotechnology(2025)10.1038/s41587-024-02551-2

N/A

0DataRank · unranked

38 citations

Kelly An, Yusuke Ito, Bhushan N. Kharbikar, Rory R Sheng, Beatriz Paredes +23 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events

npj Breast Cancer(2025)10.1038/s41523-025-00774-3

N/A

0DataRank · unranked

3 citations

Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim +7 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

FNA biopsy of breast specimens effectively harvests cells for patient‐derived organoids modeling ductal carcinoma in situ

Cancer Cytopathology(2025)10.1002/cncy.70052

N/A

0DataRank · unranked

1 citations

Nadine Goldhammer, Poonam Vohra, Shruti Warhadpande, George C. de Castro, Cristian K. Maldonado Rodas +11 more

CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

npj Breast Cancer(2025)10.1038/s41523-025-00830-y

N/A

0DataRank · unranked

1 citations

Karen S. Flatten, Taylor M. Weiskittel, Annapoorna Venkatachalam, Annabella R. Strathman, Olivia K. Rossman +17 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer

Research Square(2025)10.21203/rs.3.rs-6926989/v1

N/A

0DataRank · unranked

2 citations

Xiaopeng Sun, Ann Hanna, Andres A. Ocampo, Brandie C. Taylor, James R. Marshall +14 more

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial

Frontiers in Oncology(2025)10.3389/fonc.2025.1605120

N/A

0DataRank · unranked

0 citations

Justin Lengfeld, S.P. Stoesz, Michelle Edwards, Franklin Pass, Gillian L. Hirst +6 more

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

medRxiv(2025)10.1101/2025.08.25.25334393

N/A

0DataRank · unranked

0 citations

James M. Dolezal, Hanna M. Hieromnimon, Sara J. Venters, Sara Kochanny, Anran Li +31 more

Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial

Communications Medicine(2025)10.1038/s43856-025-01126-9

N/A

0DataRank · unranked

0 citations

Kathleen D. Liu, Derek W. Russell, D. Clark Files, Karl W. Thomas, Fady Yousef +86 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0DataRank · unranked

445 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

npj Breast Cancer(2020)10.1038/s41523-020-00203-7

N/A

0DataRank · unranked

83 citations

David C. Newitt, Jessica Gibbs, Lisa J. Wilmes, Ella F. Jones, Vignesh A. Arasu +57 more

Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective

Surgery(2020)10.1016/j.surg.2020.04.052

N/A

0DataRank · unranked

44 citations

Laura J. Esserman, Eugene J. Koay, Anirban Maitra, Yu Shen, Kimberly S. Kirkwood +2 more

Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence

Journal of Mammary Gland Biology and Neoplasia(2020)10.1007/s10911-021-09479-2

N/A

0DataRank · unranked

48 citations

Jennifer Bolen, Louis Schuetter, Pierre P. Massion, Clifford Hoyt, Scott R. VandenBerg +4 more

Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2− Patients

Journal of Breast Imaging(2020)10.1093/jbi/wbaa028

N/A

0DataRank · unranked

20 citations

Paul Kim, Wen Li, Fredrik Strand, Cody McHargue, Roy Harnish +8 more

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET

Scientific Reports(2020)10.1038/s41598-020-78865-3

N/A

0DataRank · unranked

19 citations

Wen Li, Youngho Seo, Robert R. Flavell, John Kornak, Benjamin L. Franc +5 more

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

Cancers(2020)10.3390/cancers12061511

N/A

0DataRank · unranked

18 citations

Deep Hathi, Rita I. Freimanis, Rita A. Mukhtar, A. Jo Chien, Laura J. Esserman +4 more

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial

Tomography(2020)10.18383/j.tom.2020.00006

N/A

0DataRank · unranked

17 citations

Wen Li, Jessica Gibbs, Lisa J. Wilmes, Alex Nguyen, Ella F. Jones +7 more

Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater

The American Journal of Surgery(2020)10.1016/j.amjsurg.2020.05.038

N/A

0DataRank · unranked

15 citations

Case Brabham, Ruby Guo, Kelly Fahrner-Scott, Jasmine Wong, Michael Alvarado +4 more

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy

Tomography(2020)10.18383/j.tom.2020.00009

N/A

0DataRank · unranked

11 citations

Vignesh A. Arasu, Fredrik Strand, Wen Li, Natsuko Onishi, Jessica Gibbs +6 more

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer

Tomography(2020)10.18383/j.tom.2020.00016

N/A

0DataRank · unranked

24 citations

David C. Newitt, Bo La Yun, Ella F. Jones, Vignesh A. Arasu, Lisa J. Wilmes +8 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

0DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Laura J. Esserman

Indexed papers

Top data-sharing exemplar

Papers